# Administration with carnosic acid alleviates the development of osteoarthritis by attenuating macrophage polarization-mediated inflammation and cartilage oxidative damage and degradation via regulating Nrf2/NF-kB axis

**Authors:** Yang Yang, Wenwen Ping, Jin Xu, Rong Yang

PMC · DOI: 10.3389/fimmu.2026.1710302 · Frontiers in Immunology · 2026-02-10

## TL;DR

Carnosic acid may help treat osteoarthritis by reducing inflammation and cartilage damage through a specific molecular pathway.

## Contribution

Carnosic acid is shown to regulate macrophage polarization and cartilage protection via the Nrf2/NF-kB axis in osteoarthritis.

## Key findings

- Carnosic acid inhibits M1 macrophage polarization and promotes M2-like polarization.
- It reduces oxidative injury and inflammation in chondrocytes caused by M1 macrophages.
- In mice, carnosic acid alleviates cartilage degeneration and synovitis.

## Abstract

Osteoarthritis (OA) is a common inflammatory degenerative joint disease characterized by deterioration of articular cartilage. Macrophages exert the important roles in cartilage damage and synovial inflammation in OA. Carnosic acid (CA) possesses critical function in multiple inflammatory diseases.

Macrophages were treated with carnosic acid. Chondrocytes were incubated with conditioned medium (CM) from macrophages. Then, the effects on macrophage polarization were analyzed. The effects on chondrocyte oxidative injury, inflammation and extracellular matrix (ECM) metabolism imbalance were explored. Carnosic acid was administrated to Anterior cruciate ligament transection (ACLT)-constructed OA mice model. Then, the efficacy of carnosic acid in the progression of OA was further explored.

Carnosic acid inhibited LPS-induced macrophage M1 polarization and enhanced IL-4-evoked macrophage M2-like polarization. Furthermore, conditioned medium (CM) from M1 macrophages induced chondrocyte oxidative injury, which were abrogated by carnosic acid. Concomitantly, carnosic acid restrained M1 macrophage CM-increased inflammatory mediator and inflammatory cytokine IL-6 and TNF-α contents. Moreover, carnosic acid also antagonized M1 macrophage CM-evoked extracellular matrix (ECM) degradation. Mechanistically, carnosic acid enhanced Nrf2 expression and suppressed subsequent activation of the NF-κB signaling. Intriguingly, Nrf2 inhibition restrained activation of the NF-κB signaling and reversed carnosic acid-mediated suppression on macrophage M1-like polarization. Furthermore, carnosic acid attenuated M1 macrophage-induced oxidative injury, inflammatory response and ECM metabolism disturbance of chondrocytes. In vivo, carnosic acid alleviated articular cartilage degeneration and synovitis, leading to decrease of Osteoarthritis Research Society International (OARSI) and synovitis scores. Moreover, carnosic acid attenuated oxidative stress injury and cartilage degradation in OA mice. Additionally, carnosic acid affected synovium macrophage polarization from M1 to M2 , mitigated inflammation and activation of the Nrf2/NF-kB axis in OA mice.

Carnosic acid may alleviate the progression of OA by attenuating macrophage polarization-mediated inflammatory response and cartilage oxidative damage via regulating Nrf2/NF-kB axis, supporting it as a promising and potential therapeutic agent for patients with OA in clinical practice.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Proteins:** IL6 (interleukin 6), TNF (tumor necrosis factor)
- **Chemicals:** carnosic acid (PubChem CID 65126), IL-4 (PubChem CID 171905173)
- **Diseases:** osteoarthritis (MONDO:0005178)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Cd163 (CD163 antigen) [NCBI Gene 93671] {aka CD163v2, CD163v3}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, Anxa5 (annexin A5) [NCBI Gene 11747] {aka Anx5, CPB-I}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, Adamts5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 23794] {aka 9530092O11Rik, ADAM-TS5, ADAMTS1, ADAMTS11, ADMP-2, ASMP-2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Acan (aggrecan) [NCBI Gene 11595] {aka Agc, Agc1, CSPCP, Cspg1, b2b183Clo, cmd}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}
- **Diseases:** synovitis (MESH:D013585), osteoporosis (MESH:D010024), ECM metabolism disorders (MESH:C535509), cytotoxicity (MESH:D064420), rheumatoid arthritis (MESH:D001172), arthritis (MESH:D001168), dislocation (MESH:D004204), joint destruction (MESH:D008105), joint injury (MESH:D000092464), disability (MESH:D009069), neuroinflammation (MESH:D000090862), ACLT (MESH:D000070598), degenerative joint disease (MESH:D019636), injury (MESH:D014947), gastric ulceration (MESH:D013276), CM (MESH:D020763), Inflammatory (MESH:D007249), pain (MESH:D010146), OA (MESH:D010003), metabolism disorder (MESH:D008659), Cartilage degeneration (MESH:D002357)
- **Chemicals:** indomethacin (MESH:D007213), Lipofectamine (MESH:C086724), malondialdehyde (MESH:D008315), Safranin O (MESH:C009195), NO (MESH:D009614), H&amp;E (MESH:D006371), DMEM (-), penicillin (MESH:D010406), CA (MESH:C018381), DCF (MESH:D015649), PVDF (MESH:C024865), PBS (MESH:D007854), ROS (MESH:D017382), DMSO (MESH:D004121), DAPI (MESH:C007293), CO2 (MESH:D002245), LPS (MESH:D008070), paraformaldehyde (MESH:C003043), MDA (MESH:D015104), 2', 7'-dichlorodihydrofluorescein diacetate (MESH:C110400), streptomycin (MESH:D013307), pentobarbital sodium (MESH:D010424), Triton X-100 (MESH:D017830), saline (MESH:D012965), paraffin (MESH:D010232), PI (MESH:D010716), SDS (MESH:D012967), ethanol (MESH:D000431), methotrexate (MESH:D008727), TRIzol (MESH:C411644), PGE2 (MESH:D015232), DCFH-DA (MESH:C029569)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Salvia rosmarinus (rosemary, species) [taxon 39367]
- **Cell lines:** Raw 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929504/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929504/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929504/full.md

---
Source: https://tomesphere.com/paper/PMC12929504